Note 2. Acquisitions

On May 15, 2012, we completed a business combination (the “Bios Acquisition”) by acquiring specific assets and assuming certain liabilities of Bios International Corporation (“Bios”), a New Jersey corporation. The asset acquisition agreement (the “Bios Agreement”) includes a provision for contingent consideration based on revenue growth over a three year earn-out period. The Bios Acquisition further diversifies and grows our Instruments segment, and we believe that it will maintain our historic profitability measures.

The contingent consideration arrangement requires us to pay Bios if cumulative revenues related to the acquisition for the three years subsequent to the acquisition exceed $22,127,000. The potential undiscounted future payment that we could be required to make ranges from $0 to $6,710,000. The fair value of the contingent consideration arrangement included in the purchase price below was estimated based on the historic revenue growth rates of Bios.

We expect to achieve significant savings and income growth as we integrate the operations and marketing functions. These factors, among others, contributed to a purchase price in excess of the estimated fair value of Bios’ net identifiable assets and, as a result, we recorded goodwill in connection with this transaction. The goodwill is expected to be deductible for tax purposes. All of the goodwill was assigned to our Instruments segment.

The Bios Acquisition constituted the acquisition of a business and was recognized at fair value. We determined the estimated fair values using discounted cash flow analyses and estimates made by management. The following reflects our allocation of the consideration, subject to customary purchase price adjustments in accordance with the Bios Agreement (in thousands):

Cash consideration	$	16,660
Contingent purchase price liability	2,140
Aggregate consideration	$	18,800

The purchase price was allocated as follows:
Accounts receivable, net	$	478
Inventories, net	910
Other current assets	28
Property, plant and equipment	63
Intangible assets	8,200
Goodwill	9,190
Current liabilities	(69		)
Total purchase price allocation	$	18,800

The accompanying statements of income include the results of the Bios Acquisition from the acquisition date of May 15, 2012. The pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on April 1, 2012, 2011 and 2010, are as follows (in thousands, except per share data):

	Year ended March 31,
	2013		2012		2011
Total revenues	$	47,216	$	46,498	$	40,496
Net income	8,471		8,102		6,349
Net income per common share:
Basic	$	2.52	$	2.47	$	1.97
Diluted	2.36		2.34		1.91

The above pro forma results include adjustments for amortization of acquired intangible assets, interest expense and income tax expense. The pro forma information as presented above is for informational purposes only and is not necessarily indicative of results of operations that would have been achieved if the acquisition had taken place at the dates identified.

On December 21, 2010, we completed a business combination (the “Apex Acquisition”) by purchasing the assets associated with the biological indicator line of products of Apex Laboratories, Inc. The products acquired include their biological indicators for use in vapor hydrogen peroxide disinfection processes. The purchase price consisted of a $6,452,000 in cash and an accounts receivable settlement of $38,000. The purchase price also included a $600,000 holdback that accrued interest at two percent per annum.

Accounts Receivable, net	$	544
Inventories, net	65
Property and equipment	49
Intangible assets	4,571
Goodwill	1,261
	$	6,490

On April 27, 2010, we purchased SGM Biotech, Inc. located in Bozeman, Montana. Under the terms of the agreement, we acquired all of the common stock of SGM Biotech, Inc. for $12,083,000 in cash. We incurred approximately $168,000 in third party acquisition costs related to this transaction. On April 30, 2010, we also acquired from the former owners of SGM Biotech, Inc. the facility that houses the operations for an additional $2,150,000.

The transaction constituted the acquisition of a business and was recognized at fair value. We determined the estimated fair value using discounted cash flow analyses and estimates made by management. The difference between the purchase price and the carryover tax basis was not deductible for tax purposes, resulting in a deferred tax liability. The purchase price allocation was as follows (in thousands):

Accounts receivable, net	$	1,116
Inventories, net	758
Other assets	195
Property and equipment	1,035
Liabilities	(1,021		)
Deferred tax liability	(2,358		)
Intangible assets	5,434
Goodwill	6,924
	$	12,083